The department was the winner of the Department of Excellence 2023-27 project with funding of 8 million euros and 409 thousand in university co-funding for PhDs. In addition, it participates in PNRR projects as leader of Spoke 1 of the "CN3 National Research Center Development of Gene Therapy and Drugs with RNA Technology" with a total Unimore funding of 8 million euros, and in the project proposal HEALTH ITALY theme 6 as leader of SPOKE 6, with a total Unimore funding of 7 million euros. It should be noted that this funding also positively impacts the research activities of other Unimore departments whose faculty members are involved in the above projects. PNRR funding will contribute to the achievement of several of the goals set in the Strategic Plan.

Regarding general research directives, the Department:

(A) Studies the molecular basis and pathogenetic mechanisms of diseases with high clinical-epidemiological impact, such as hereditary-metabolic, infectious, hematologic, oncologic, degenerative, inflammatory-chronic, and rheumatologic diseases (basic understanding work package).

(B) Implements molecular, genetic, immunological, and advanced radiological imaging diagnostic programs (advanced diagnostic work package).

(C) Develops innovative therapies based on cell and gene therapy techniques, robotic, videothoracoscopic, skull base surgery integrated with cutting-edge surgical and microsurgical, orthopedic, and plastic reconstructive procedures as well as drug therapies directed toward specific molecular targets (therapeutic work package).

(D) Implements, with a multidisciplinary approach, a research culture marked by innovation, clinical and industrial transferability (of third mission) through new biological knowledge and interdisciplinarity.